Form SC 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0001193125-21-102332
Filing Date
2021-03-31
Accepted
2021-03-31 16:31:54
Documents
2

Document Format Files

Seq Description Document Type Size
1 SC 13D d116955dsc13d.htm SC 13D 73734
2 EX-99.1 d116955dex991.htm EX-99.1 34372
  Complete submission text file 0001193125-21-102332.txt   109699
Mailing Address TUBORG HAVNEVEJ 19 HELLERUP G7 2900
Business Address TUBORG HAVNEVEJ 19 HELLERUP G7 2900 45 8824 8824
Novo Holdings A/S (Filed by) CIK: 0001388325 (see all company filings)

EIN.: 000000000 | State of Incorp.: G7 | Fiscal Year End: 1231
Type: SC 13D

Mailing Address C/O ORBIMED ADVISORS LLC 601 LEXINGTON AVE, 54TH FLR. NEW YORK NY 10022
Business Address C/O ORBIMED ADVISORS LLC 601 LEXINGTON AVE, 54TH FLR. NEW YORK NY 10022 212-739-6451
Edgewise Therapeutics, Inc. (Subject) CIK: 0001710072 (see all company filings)

EIN.: 821725586 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-92424 | Film No.: 21793871
SIC: 2834 Pharmaceutical Preparations